Bas P M Verhaegh

Bas P M Verhaegh

Auto-generated profile, based on publicly available information

Bas P M Verhaegh

Department of Gastroenterology, Laurentius Hospital , Roermond

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Journal of Crohn's and Colitis
Verified
Journal Article
Open access
PDF file
BVBas P M Verhaegh
Bas P M Verhaegh
AMAndreas Munch
Andreas Munch
DGDanila Guagnozzi
Danila Guagnozzi
SWSigne Wildt
Signe Wildt
WCWojciech Cebula
Wojciech Cebula
LMLars K Munck
Lars K Munck
Background and Aims: The disease course of microscopic colitis [MC] is considered chronic but benign. However, this assumption is based on mainly retrospective studies, reporting on incomplete follow-up of selective cohorts. Systematic, prospective and unbiased data to inform patients and healthcare professionals on the expected course of the disease and real-life response to therapy are warranted. Methods: A prospective, pan-European, multi-centre, web-based registry was established. Incident cases of MC were included. Data on patient characteristics, symptoms, treatment and quality of life were systematically registered at baseline and during real-time follow-up. Four disease course phenotypes were discriminated and described. Results: Among 381 cases with complete 1-year follow-up, 49% had a chronic active or relapsing disease course, 40% achieved sustained remission after treatment and 11% had a quiescent course. In general, symptoms and quality of life improved after 3 months of follow-up. A relapsing or chronic active disease course was associated with significantly more symptoms and impaired quality of life after 1 year. Conclusions: A minority of MC patients follow a quiescent disease course with spontaneous clinical improvement, whereas the majority suffer a chronic active or relapsing disease course during the first year after diagnosis, with persisting symptoms accompanied by a significantly impaired quality of life.

28 September 2023 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
PDF file
TZTenghao Zheng
Tenghao Zheng
GRGiulia Roda
Giulia Roda
YZYamile Zabana
Yamile Zabana
CECelia Escudero-Hernández
Celia Escudero-Hernández
XLXingrong Liu
Xingrong Liu
MDMauro D'Amato
Mauro D'Amato
Microscopic colitis (MC) is currently regarded as an inflammatory bowel disease that manifests as two subtypes: collagenous colitis (CC) and lymphocytic colitis (LC). Whether these represent a clinical continuum or distinct entities is, however, an open question. Genetic investigations may contribute important insight into their respective pathophysiology. We conducted a GWAS meta-analysis in 1,498 CC and 373 LC patients and 13,487 controls from Europe and US, combined with publicly available MC GWAS data from UK Biobank and FinnGen (2,599 MC cases and 552,343 controls in total). HLA alleles and polymorphic residues were imputed and tested for association, including conditional analyses for the identification of key causative variants and residues. Genetic correlations with other traits and diagnoses were also studied. We detected strong HLA association with CC, and conditional analyses highlighted the DRB1*03:01 allele and its residues Y26, N77 and R74 as key to this association (best P=1.4×10 -23, OR=1.96). Nominally significant genetic correlations were detected between CC and Pneumonia (rg=0.77; P=0.048) and oesophageal diseases (rg=0.45, P=0.023). An additional locus was identified in MC GWAS analyses near the CLEC16A and RMI2 genes on chromosome 16 (rs35099084, P=2.0×10 -8, OR=1.31). No significant association was detected for LC. Our results suggest CC and LC have distinct pathophysiological underpinnings, characterised by an HLA predisposing role only in CC. This challenges existing classifications, eventually calling for a re-evaluation of the utility of MC umbrella definitions.

28 August 2019 in Environmental Research
Verified
Journal Article
Closed access
BVBas P.M. Verhaegh
Bas P.M. Verhaegh
EBEsmee M. Bijnens
Esmee M. Bijnens
THTim R.A. van Den Heuvel
Tim R.A. van Den Heuvel
DGDanny Goudkade
Danny Goudkade
MZMaurice P. Zeegers
Maurice P. Zeegers
MPMarieke J. Pierik
Marieke J. Pierik

30 June 2025 in Journal of Crohn's and Colitis
Verified
Journal Article
Closed access
BVBas P M Verhaegh
Bas P M Verhaegh
AMAndreas Munch
Andreas Munch
DGDanila Guagnozzi
Danila Guagnozzi
SWSigne Wildt
Signe Wildt
WCWojciech Cebula
Wojciech Cebula
T[the European Microscopic Colitis Group [EMCG]
the European Microscopic Colitis Group [EMCG]
Background and Aims: The disease course of microscopic colitis is largely unknown and current knowledge is based on retrospective data. The aim of the PRO-MC Collaboration is to prospectively describe the long-term disease course and prognostic factors. Methods: Incident patients of microscopic colitis were included in a prospective, European, multicenter, web-based registry. Data on patient characteristics, symptoms, treatment, and quality of life were systematically registered at baseline and during fixed follow-up intervals. Four disease course phenotypes were defined. Results: Of 422 registered incident patients, 220 had a complete 5-year follow-up. After 5 years, 6% had a quiescent disease course, 54% achieved remission after treatment, 33% had a relapsing disease course, and 7% a chronic active disease course. Patients with a relapsing or chronic active disease course had a more impaired quality of life and were more often in need for long-term budesonide treatment. The disease course in the first year after diagnosis was the only predictor of the disease course. Conclusions: Microscopic colitis is a chronic condition with relapsing or continuous disease course in nearly half of the patients during the first 5 years after diagnosis. The disease course in the first year predicts the long-term disease course.